XGN

Exagen Inc. (NASDAQ:XGN) is a medical diagnostics company founded in 2002 and headquartered in Vista, California. The company went public in September 2019 and specializes in developing and commercializing blood-based diagnostic tests for autoimmune diseases, particularly systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Exagen has built its business around proprietary cell-bound complement activation products technology, which it markets under the AVISE brand to help rheumatologists diagnose, monitor, and manage patients with complex autoimmune conditions.